Product Description
For Chronic Obstructive Pulmonary Disease (COPD). a new bronchodilator indicated for treatment of chronic obstructive pulmonary disease (COPD). (Sourced from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002974-20/BE; https://pubmed.ncbi.nlm.nih.gov/16030078/)
Mechanisms of Action: LAM Antagonist, mAChR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Inhalant
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Cyprus | Dominican Republic | Egypt | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Jordan | Malaysia | Mexico | Morocco | New Zealand | Pakistan | Philippines | Poland | Romania | Russia | South Africa | Spain | Sri Lanka | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Chronic Obstructive Pulmonary Disease|Dyspnea|Respiratory Tract Infections|Asthma|Respiratory Aspiration|Emphysema|Bronchitis, Chronic
Phase 3: Respiratory Aspiration|Chronic Obstructive Pulmonary Disease|Asthma|Cystic Fibrosis|Dyspnea
Phase 2: Non-Small-Cell Lung Cancer|Asthma|Chronic Obstructive Pulmonary Disease|Small Cell Lung Cancer|Dyspnea|Respiratory Aspiration
Phase 1: Chronic Obstructive Pulmonary Disease|Kidney Diseases|Healthy Volunteers|Spinal Cord Injuries
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06170125 |
TRITON | N/A |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2025-03-01 |
2024-02-21 |
||
NCT06525051 |
GiresunU-PULMONOLOGY-HB-01 | N/A |
Completed |
Glaucoma, Angle-Closure|Chronic Obstructive Pulmonary Disease |
2024-03-30 |
2025-08-27 |
Primary Endpoints |
|
NCT05402020 |
NCT05402020 | N/A |
Completed |
Chronic Obstructive Pulmonary Disease |
2023-02-13 |
2024-08-10 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT05393245 |
NCT05393245 | N/A |
Completed |
Chronic Obstructive Pulmonary Disease |
2022-12-07 |
2024-06-13 |
Primary Endpoints|Treatments |
|
NCT04994574 |
ACHIEVE | N/A |
Unknown status |
Chronic Obstructive Pulmonary Disease |
2022-11-01 |
2025-08-27 |
Primary Endpoints |
|
ChiCTR2000033901 |
ChiCTR2000033901 | N/A |
Recruiting |
Chronic Obstructive Pulmonary Disease |
2022-06-01 |
|||
NCT05169424 |
NCT05169424 | N/A |
Completed |
Chronic Obstructive Pulmonary Disease |
2021-12-27 |
2023-10-20 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT05501639 |
NCT05501639 | N/A |
Completed |
Asthma |
2021-11-02 |
2022-08-16 |
Primary Endpoints |
|
NCT05179512 |
DUPLICATE-INSPIRE | N/A |
Completed |
Chronic Obstructive Pulmonary Disease |
2021-08-30 |
2022-01-06 |
Primary Endpoints|Treatments |
|
NCT05083429 |
DUPLICATE-POET-COPD | N/A |
Completed |
Chronic Obstructive Pulmonary Disease |
2021-08-09 |
2021-10-20 |
Primary Endpoints|Treatments |
|
ChiCTR2100043592 |
ChiCTR2100043592 | N/A |
Not yet recruiting |
Asthma|Chronic Obstructive Pulmonary Disease |
2021-04-30 |
|||
NCT04999930 |
FF-2019-462 | N/A |
Completed |
Chronic Obstructive Pulmonary Disease |
2021-02-28 |
2021-08-12 |
Primary Endpoints |
|
NCT02864407 |
NCT02864407 | N/A |
Completed |
Chronic Obstructive Pulmonary Disease |
2021-01-20 |
2022-01-20 |
Patient Enrollment|Primary Endpoints|Treatments |
|
ACTRN12619001108101p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Mental Fatigue |
2021-01-01 |
|||
NCT04147572 |
TIOPIF | N/A |
Completed |
Chronic Obstructive Pulmonary Disease|Respiratory Aspiration |
2020-01-13 |
2019-11-23 |
Primary Endpoints|Treatments |
|
NCT04850144 |
TESSA | P1 |
Completed |
Healthy Volunteers |
2021-10-04 |
12% |
2021-10-26 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06679465 |
NCT06679465 | P4 |
Not yet recruiting |
Asthma |
2027-01-01 |
2024-11-08 |
Primary Endpoints|Treatments |
|
2023-507304-32-00 |
ANTES B+ | P4 |
Completed |
Chronic Obstructive Pulmonary Disease |
2025-01-23 |
2025-05-02 |
Treatments |
|
NCT05165485 |
PIFR-2 | P4 |
Completed |
Respiratory Aspiration|Chronic Obstructive Pulmonary Disease |
2023-11-13 |
2023-12-20 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT04231214 |
19-01 SPIOMI | P4 |
Completed |
Chronic Obstructive Pulmonary Disease |
2023-04-18 |
2023-04-27 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
ACTRN12620000935932 |
ACTRN12620000935932 | P4 |
Completed |
Asthma |
2021-12-07 |
2026-02-06 |
||
NCT03964207 |
NCT03964207 | P4 |
Completed |
Chronic Obstructive Pulmonary Disease |
2021-10-19 |
2023-10-15 |
Primary Endpoints|Treatments |
|
NCT02872090 |
LAB-Card | P4 |
Completed |
Chronic Obstructive Pulmonary Disease |
2021-06-01 |
2021-08-05 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT04223843 |
TRONARTO | P4 |
Completed |
Chronic Obstructive Pulmonary Disease |
2020-09-07 |
2020-10-06 |
Primary Endpoints|Treatments|Trial Status |
|
NCT03395002 |
NEU-01.17 | P4 |
Completed |
Chronic Obstructive Pulmonary Disease |
2020-04-30 |
2020-06-22 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Trial Status |